Literature DB >> 9294203

Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses.

C M Posavad1, D M Koelle, M F Shaughnessy, L Corey.   

Abstract

The specific mechanisms underlying the varied susceptibility of HIV-infected (HIV+) individuals to opportunistic infections (OI) are still incompletely understood. One hypothesis is that quantitative differences in specific T cell responses to a colonizing organism determine the development of an AIDS-defining OI. We evaluated this hypothesis for herpes simplex virus (HSV) infection, a common OI in HIV+ patients. Using limiting dilution analyses, the frequency of HSV-specific CD8+ cytotoxic T lymphocyte precursors (pCTL) and proliferative precursors were quantitated in peripheral blood mononuclear cells from 20 patients coinfected with HIV and HSV-2. The frequency of HSV-specific CD8+ pCTL in HSV+HIV+ individuals was significantly lower than in HSV+HIV- individuals (1 in 77,000 vs. 1 in 6,000, P = .0005) and was not different than in HSV-HIV- individuals (1 in 100,000, P = .24). HIV+ patients who suffered more severe genital herpes recurrences had significantly lower HSV-specific CD8+ pCTL frequencies than those patients with mild recurrences (1 in 170,000 vs. 1 in 26,000, P = .03). In contrast, no significant difference was seen in proliferative precursor frequencies between those patients with mild vs. severe genital herpes (1 in 3,800 vs. 1 in 6,600, P > .5). Quantitative differences in pCTL frequency to HSV appear to be the most important host factor influencing the frequency and severity of HSV reactivation in HIV+ patients. Studies to reconstitute such immunity, especially in people with acyclovir-resistant HSV, appear warranted.

Entities:  

Mesh:

Year:  1997        PMID: 9294203      PMCID: PMC23355          DOI: 10.1073/pnas.94.19.10289

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Variation in lymphoproliferative responses during recrudescent orofacial herpes simplex virus infections.

Authors:  J P Vestey; M Norval; S Howie; J Maingay; W A Neill
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

2.  T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and type 2.

Authors:  M A Carmack; L L Yasukawa; S Y Chang; C Tran; F Saldana; A M Arvin; C G Prober
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

3.  Herpes simplex virus resistant to acyclovir. A study in a tertiary care center.

Authors:  J A Englund; M E Zimmerman; E M Swierkosz; J L Goodman; D R Scholl; H H Balfour
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

4.  Recurrent herpes simplex virus type 1 infection precipitated by the impaired production of interleukin-2, alpha-interferon, and cell-mediated cytotoxicity.

Authors:  Y C Kuo; C Y Lin
Journal:  J Med Virol       Date:  1990-07       Impact factor: 2.327

5.  Enumeration of viral antigen-reactive helper T lymphocytes in human peripheral blood by limiting dilution for analysis of viral antigen-reactive T-cell pools in virus-seropositive and virus-seronegative individuals.

Authors:  K A Clouse; P W Adams; C G Orosz
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

6.  Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection.

Authors:  R Enzensberger; W Braun; C July; E B Helm; H W Doerr
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

7.  Helper activity in antigen-specific antibody production mediated by CD4+ human cytotoxic T cell clones directed against herpes simplex virus.

Authors:  M Yasukawa; A Inatsuki; Y Kobayashi
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

8.  Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens.

Authors:  M A Tigges; D Koelle; K Hartog; R E Sekulovich; L Corey; R L Burke
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes.

Authors:  D M Margolis; A B Rabson; S E Straus; J M Ostrove
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

10.  Lymphoproliferative responses in recrudescent orofacial herpetic infections.

Authors:  J P Vestey; M Norval; S E Howie
Journal:  J R Soc Med       Date:  1990-05       Impact factor: 18.000

View more
  46 in total

1.  Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor.

Authors:  David M Koelle; Zhi Liu; Christopher L McClurkan; Randal C Cevallos; Jeffrey Vieira; Nancy A Hosken; Clement A Meseda; Devon C Snow; Anna Wald; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

Review 2.  Viral modulation of T-cell receptor signaling.

Authors:  Keith R Jerome
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

3.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

4.  An extract of Stephania hernandifolia, an ethnomedicinal plant, inhibits herpes simplex virus 1 entry.

Authors:  Joy Mondal; Ananya Das Mahapatra; Keshab C Mandal; Debprasad Chattopadhyay
Journal:  Arch Virol       Date:  2021-05-26       Impact factor: 2.574

5.  CXCL17 Chemokine-Dependent Mobilization of CXCR8+CD8+ Effector Memory and Tissue-Resident Memory T Cells in the Vaginal Mucosa Is Associated with Protection against Genital Herpes.

Authors:  Ruchi Srivastava; Marcela Hernández-Ruiz; Arif A Khan; Mona A Fouladi; Grace J Kim; Vincent T Ly; Taikun Yamada; Cynthia Lam; Sheilouise A B Sarain; Undariya Boldbaatar; Albert Zlotnik; Elmostafa Bahraoui; Lbachir BenMohamed
Journal:  J Immunol       Date:  2018-03-16       Impact factor: 5.422

6.  A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice.

Authors:  Patric Lundberg; Paula Welander; Harry Openshaw; Christina Nalbandian; Carl Edwards; Lyle Moldawer; Edouard Cantin
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection.

Authors:  A X Holterman; K Rogers; K Edelmann; D M Koelle; L Corey; C B Wilson
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.

Authors:  Bulbulgul Aumakhan; Charlotte A Gaydos; Thomas C Quinn; Chris Beyrer; Lorie Benning; Howard Minkoff; Daniel J Merenstein; Mardge Cohen; Ruth Greenblatt; Marek Nowicki; Kathryn Anastos; Stephen J Gange
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

9.  Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.

Authors:  Alison J Johnson; Michelle H Nelson; Melanie D Bird; Chin-Fun Chu; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2009-11-25       Impact factor: 4.054

10.  Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects.

Authors:  David M Koelle; Amalia Magaret; Christopher L McClurkan; Michael L Remington; Terri Warren; Florentina Teofilovici; Anna Wald
Journal:  Clin Vaccine Immunol       Date:  2008-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.